Oncology immunisation programme
The incidence of malignant tumours increases, and cancer is characterized by the rapid creation of abnormal cells, whose abnormal growth can enter the immediate vicinity of the body and spread to other organs, known as transfer. Widespread transfer is the leading cause of cancer deaths. With the increasing incidence of cancer and mortality in China, there is a trend towards rejuvenation. More than half of global oesophagus cancer is also increasing in China. As a result, cancer was diagnosed mostly in the middle and late stages, and treatment was relatively less effective at an early stage. Good dependence and home-based care can be beneficial to survival.
From the end of the nineteenth century – surgically excised tumours, from the end of the nineteenth century – from the use of high energy waves (e.g. X-rays) to kill tumour cells, from the 1950s – from the use of cytotoxic drugs to inhibit tumour growth. By the end of the 20th century, the target-target treatment had rendered it inactive by identifying specific protein target points for tumour cells, locating tumour cells, targeting targets in the October 21st century — not tumour cells and tissues, but by activation of the human own immune system. The most widely used immunosuppressant is now the PD-1/PD-L1 inhibitor, which treats multiple tumours. The CAR-T-armed immunocellular cell integrates the cancer cell “positioning device” CAR into the T-cell, which is targeted at blood tumours.
Pre-immuno-test assessment of the likelihood of benefits and availability of medicines. Key indicators examine PD-L1 expression level 1 (the higher the level of PD-L1 expressed by cancer cells, the greater the likelihood that patients will benefit from PD-1/PD-L1 inhibitor treatment) tumour mutation load (TMB) (microsatellite highly unstable (MSI-H) biochemical indicators of blood, liver and kidney function, etc.; treatment according to the therapeutic process: determination of treatment programmes and adherence to treatment assessment treatments for long and, if necessary, programme adjustments. Long-term maintenance of immunotherapy increases the benefits of survival, with normal cells divided up to a maximum of 50 times, but cancer cells multiply indefinitely. Without early and effective treatment, there may be rapid progress and diversion to reduce survival. When cancer is detected, effective treatment should be provided as soon as possible to slow progress and the transfer of cancer cells; the treatment of late lung cancer should be based on a comprehensive treatment approach that develops individualized treatment strategies based on the patient ‘ s pathology, molecular genetic characteristics and physical state, with a view to maximizing the patient ‘ s survival, controlling the rate of progress of the disease and improving the quality of life.
Immunisation treatment is a front-line drug for extensive small-cell lung cancer and non-small-cell lung cancer, which can help patients improve their survival and quality of life; it can also be used before and after the operation to reduce the tumour and increase the chances of surgery. However, the incidence at the time of the immunotherapy infusion was about 10 per cent, with most minor symptoms fixed during the first infusion: fever, rigidity, itching, low blood pressure, chest incommodity, rashes, measles, vascular edema, asthma or hysteria, including allergies (for urgent treatment) should be followed closely within three hours of the discharge, and in case of discomfort, medical personnel should be informed in a timely manner; family support is preferred in the hospital.
Immunization treatments continue to provide survival benefits to patients on tumours, sustain long-term immunisation treatments, with greater survival benefits, and most of the adverse effects of immunisation treatments are moderate and largely reversible if they are detected early.
